New inhaled drug shows promise for COPD in Long-Term trial
NCT ID NCT07425210
First seen Feb 21, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This study is testing a new inhaled medication (HSK39004) for people with moderate-to-severe chronic obstructive pulmonary disease (COPD). About 300 adults aged 40 to 80 will take the drug twice daily for 52 weeks to see if it is safe and helps control their condition. The goal is to manage the disease long-term, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE LUNG DISEASE (COLD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guizhou Provincial People's Hospital
Guiyang, Guizhou, 550002, China
Conditions
Explore the condition pages connected to this study.